Biomarker Discovery
Proven and Successful Track Record in Novel Biomarker Discovery
Proteome Sciences has been at the forefront of Proteomics research and discovery since the early 1990s, and has a long and successful track record in discovering new and valuable biomarkers to further drug discovery and clinical diagnostic applications. Separate to our comprehensive
PS Biomarker ServicesTM CRO business, we actively reinvest in and conduct original biomarker research and discovery programs both independently and in collaboration with leading research partners.
Together with our Discovery research partners, Proteome Sciences has built a large repertoire of proprietary biomarker content for many important diseases
The human proteome is an extremely complex and dynamic entity which has the potential to reflect the multiple biological processes underlying health and disease. Unlike the genome which remains static through life, the proteome changes in real time response to changes in health status. Our challenge is to identify the most reliable, consistent changes associated with each disease and produce a map to help guide the selection of best treatment options. Through these efforts proteomics is providing the biomarker content for Personalized Medicine.
Proteome Sciences has an extensive collaborative and research partner network, married with world leading in-house scientific expertise, state-of-the-art analytical instrumentation, data analysis and bioinformatics capabilities. Based on three component modules – Discovery, Validation, Implementation – we are unique in providing a full service offering to rapidly apply biomarker strategies to all phases of drug development and for the production of new diagnostic products.
At the core of Proteome Sciences technologies and expertise, is a first-in-class mass spectrometry capability for the detection and accurate quantitation of biomarkers. Many assays utilize Proteome Sciences’ proprietary Tandem Mass Tags® / TMT®, (commercially available through Thermo Scientific), labeling technology to ensure the most accurate and consistent results expected by today’s researchers. TMT® labeling of proteins and peptides allows tighter control on analytical variability during discovery with subsequent rapid development of mass spectrometry assays for biomarker validation. We also utilize the latest in immunological assays to further our Discovery programs and as important Validation tools through PS Biomarker ServicesTM.
Mass spectrometry permits the rapid identification of novel biomarkers from a far greater spectrum of the proteome than can be achieved using an immunoassay approach alone
Proteome Sciences has active interest in the following diseases with two areas of particular research focus being Cancer and CNS related diseases.
Contact us to learn more about our partnering with Proteome Sciences or to arrange a consultation with our scientists for your Biomarker Discovery project.
